133 related articles for article (PubMed ID: 25213457)
21. Genetics of high-dose methotrexate-induced oral mucositis: current perspectives.
Heil SG
Pharmacogenomics; 2019 Jun; 20(9):621-623. PubMed ID: 31250729
[No Abstract] [Full Text] [Related]
22. Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies.
Tsujimoto S; Yanagimachi M; Tanoshima R; Urayama KY; Tanaka F; Aida N; Goto H; Ito S
Pediatr Blood Cancer; 2016 Nov; 63(11):1983-9. PubMed ID: 27399166
[TBL] [Abstract][Full Text] [Related]
23. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
Seidemann K; Book M; Zimmermann M; Meyer U; Welte K; Stanulla M; Reiter A
Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
[TBL] [Abstract][Full Text] [Related]
24. Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.
Turello R; Rentsch K; Di Paolo E; Popovic MB
Pediatr Blood Cancer; 2008 Jan; 50(1):154-6. PubMed ID: 17387702
[TBL] [Abstract][Full Text] [Related]
25. 677TT genotype is associated with elevated risk of methotrexate (MTX) toxicity in juvenile idiopathic arthritis: treatment outcome, erythrocyte concentrations of MTX and folates, and MTHFR polymorphisms.
Tuková J; Chládek J; Hroch M; Nemcová D; Hoza J; Dolezalová P
J Rheumatol; 2010 Oct; 37(10):2180-6. PubMed ID: 20595278
[TBL] [Abstract][Full Text] [Related]
26. Genetic markers in methotrexate treatments.
Giletti A; Esperon P
Pharmacogenomics J; 2018 Dec; 18(6):689-703. PubMed ID: 30237581
[TBL] [Abstract][Full Text] [Related]
27. 667C>T and 1298A>C polymorphisms of MTHFR do not predict response to methotrexate in patients with gestational trophoblastic neoplasia.
Lasecka L; Dixon PH; Molokhia M; Sharma N; Schleh A; Wang CM; Steel JH; Seckl MJ; Savage PM; Fisher RA
Gynecol Oncol; 2011 Dec; 123(3):605-9. PubMed ID: 21920590
[TBL] [Abstract][Full Text] [Related]
28. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
[TBL] [Abstract][Full Text] [Related]
29. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.
van Kooten Niekerk PB; Schmiegelow K; Schroeder H
Eur J Haematol; 2008 Nov; 81(5):391-8. PubMed ID: 18691257
[TBL] [Abstract][Full Text] [Related]
30. Advances in individual prediction of methotrexate toxicity: a review.
Schmiegelow K
Br J Haematol; 2009 Sep; 146(5):489-503. PubMed ID: 19538530
[TBL] [Abstract][Full Text] [Related]
31. Adverse drug reaction to methotrexate: pharmacogenetic origin.
Przekop PR; Tulgan H; Przekop AA; Glantz M
J Am Osteopath Assoc; 2006 Dec; 106(12):706-7. PubMed ID: 17242415
[TBL] [Abstract][Full Text] [Related]
32. Relationship of MTHFR and NQO1 Pharmacogenetics and Chemotherapy Clinical Outcomes in Breast Cancer Patients.
Chaturvedi P; Tulsyan S; Agarwal G; Lal P; Agrawal S; Mittal RD; Mittal B
Biochem Genet; 2015 Aug; 53(7-8):211-22. PubMed ID: 26014925
[TBL] [Abstract][Full Text] [Related]
33. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
Marcuello E; Altés A; Menoyo A; Rio ED; Baiget M
Cancer Chemother Pharmacol; 2006 Jun; 57(6):835-40. PubMed ID: 16187112
[TBL] [Abstract][Full Text] [Related]
34. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants.
D'Angelo V; Ramaglia M; Iannotta A; Crisci S; Indolfi P; Francese M; Affinita MC; Pecoraro G; Napolitano A; Fusco C; Oreste M; Indolfi C; Casale F
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1339-46. PubMed ID: 21590445
[TBL] [Abstract][Full Text] [Related]
35. Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism.
Strunk T; Gottschalk S; Goepel W; Bucsky P; Schultz C
Med Pediatr Oncol; 2003 Jan; 40(1):48-50. PubMed ID: 12426687
[No Abstract] [Full Text] [Related]
36. Managing reduced methotrexate clearance in a patient with a heterozygous methylenetetrahydrofolate reductase gene polymorphism.
Gammon DC; Bhatt MS; Patel B; Anderson M; Van Horn A; Glantz MJ
J Oncol Pharm Pract; 2008 Sep; 14(3):153-6. PubMed ID: 18719070
[TBL] [Abstract][Full Text] [Related]
37. The effect of RFC G80A polymorphism in Cretan children with acute lymphoblastic leukemia and its interaction with MTHFR C677T and A1298C polymorphisms.
Karathanasis NV; Stiakaki E; Goulielmos GΝ; Kalmanti M
Int J Lab Hematol; 2014 Aug; 36(4):425-30. PubMed ID: 24237708
[TBL] [Abstract][Full Text] [Related]
38. Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate.
Choi YJ; Park H; Lee JS; Lee JY; Kim S; Kim TW; Park JS; Kim JE; Yoon DH; Suh C
Hematol Oncol; 2017 Dec; 35(4):504-509. PubMed ID: 27781293
[TBL] [Abstract][Full Text] [Related]
39. Study on Relationships of Tumor Status and Gene Polymorphism With Blood Concentration of MTX and Toxicities in 63 Pediatric Mature B Cell Lymphoma in Chinese Population.
Huang S; Jin L; Yang J; Duan LY; Zhang M; Zhou JC; Zhang HY
Technol Cancer Res Treat; 2021; 20():1533033821995288. PubMed ID: 33752528
[TBL] [Abstract][Full Text] [Related]
40. [Association between the methylenetetrahydrofolate reductase gene polymorphisms and haplotype with toxicity response of high dose methotrexate chemotherapy].
Liao QC; Li XL; Liu ST; Zhang Y; Li TY; Qiu JC
Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Jul; 33(7):735-9. PubMed ID: 22968027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
